CTRI/2022/01/039287已完成4 期
A Prospective, Multicenter, Open-Label, Single-Arm, Post Marketing Observational Studyto Assess the Effectiveness and Safety of Prochlorperazine In Patients with Acute Vertigo
试验速览
- 阶段
- 4 期
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •1. Patients of either sex in the age group of 18-65 years.
- •2. Patients diagnosed with Meniere’s disease, vestibular neuritis, labyrinthitis, or
- •post-operative vertigo.
- •3. Patients willing to participate in the study and sign an informed consent form
排除标准
- •1. Patients diagnosed with BPPV.
- •2. Patients with history of psychiatric illness.
- •3. Patients on anti-psychotic or anti-depressant medication.
- •4. Patients with history of cardiovascular, kidney or liver disorder.
- •5. Patients requiring hospitalization for any cause.
- •6. Patients with suspected or established subcortical brain damage, with or without
- •hypothalamic damage.
- •7. Pregnant and nursing women.
- •8. Women with childbearing potential who are not practicing a reliable method of birth
- •9. Patients with a known history of hypersensitivity to phenothiazine derivatives
研究者
相似试验
招募中
Unknown
To assess the efficacy, safety and tolerability of CELNUTRA 2.0 and Kitchen feed in the Intensive Care Unit PatientsCTRI/2023/05/052938ucgenex lifesciences Pvt. Limited
进行中（未招募）
1 期
A clinical trial to study the effects of selexipag on the heart in patients with Pulmonary Arterial HypertensioMedDRA version: 21.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersPulmonary Arterial HypertensionEUCTR2019-004783-22-FRACTELION Pharmaceuticals Ltd.80
已完成
4 期
A Prospective, Multicenter, Single-Arm, Open-Label, Phase 4 Study of the Effects of Selexipag on Right Ventricular Remodeling in Pulmonary Arterial Hypertension Assessed by Cardiac Magnetic Resonance Imaging. (RESTORE)pulmonary arterial hypertensionPAHNL-OMON52455Actelion Pharmaceuticals5
进行中（未招募）
1 期
A clinical trial to study the effects of selexipag on the heart in patients with Pulmonary Arterial HypertensioMedDRA version: 21.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersPulmonary Arterial HypertensionEUCTR2019-004783-22-NLACTELION Pharmaceuticals Ltd.80
进行中（未招募）
1 期
A clinical trial to study the effects of selexipag on the heart in patients with Pulmonary Arterial HypertensioMedDRA version: 21.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersPulmonary Arterial HypertensionEUCTR2019-004783-22-DEACTELION Pharmaceuticals Ltd.80